期刊文献+

术前强化他汀治疗对冠心病患者冠脉介入治疗预后的影响 被引量:1

Effect of preoperative intensive statin therapy on prognosis of patients with coronary heart disease after percutaneous coronary intervention
下载PDF
导出
摘要 目的探讨术前强化他汀治疗对冠心病患者冠脉介入治疗预后的影响。方法选取2016年4月至2018年4月在本院接受治疗的40例冠心病患者,均采用冠脉介入治疗,按照入院顺序分成观察组与对照组,对照组术前术后均常规应用20 mg阿托伐他汀,观察组术前应用40 mg阿托伐他汀治疗,术后应用20 mg阿托伐他汀,观察两组患者手术前后肌酸激酶同工酶(CK-MB)、肌钙蛋白-I(TNI)、C反应蛋白(CRP)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、三酰甘油(TG)水平及不良心血管事件。结果对照组术后24 h的CK-MB、TNI、CRP水平均明显提高,与观察组术后24 h对比差异有统计学意义(P<0.05);两组患者术后1个月LDL-C、HDL-C、TC、TG均有明显改善,与术前对比差异有统计学意义(P<0.05),但两组组间差异无统计学意义;术后1年随访,观察组不良心血管事件发生率5.00%显著低于对照组15.00%,差异有统计学意义(P<0.05)。结论术前强化他汀治疗对冠心病患者冠脉介入治疗具有显著效果,可促进机体的稳定性,预防不良心血管事件,值得临床推广使用。 Objective To investigate the effect of preoperative intensive statin therapy on the prognosis of patients with coronary heart disease after percutaneous coronary intervention. Methods 40 patients with coronary heart disease who were treated in our hospital in April 2016 to April2018 were treated with coronary intervention. The patients were divided into the observation group and the control group according to the order of admission. The control group was routinely used 20 mg atorvastatin before and after the operation. The observation group was treated with 40 mg atorvastatin before operation, and 20 mg atorvastatin was applied after the operation. In the two groups, the creatine kinase isoenzyme(CK-MB), troponin-I(TNI), C reactive protein(CRP), low density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), total cholesterol(TC), three acyl glycerol(TG), and adverse cardiovascular events were observed before and after the operation. Results The level of CK-MB, TNI and CRP of 24 h in the control group increased significantly after operation, and the difference of 24 h in the observation group was statistically significant(P<0.05). The two groups were significantly improved in 1 months after the operation, LDL-C, HDL-C, TC and TG were significantly improved(P<0.05), but there was no significant statistical difference between the two groups. After 1 years of follow-up, the incidence of adverse cardiovascular events in the observation group was 5% significantly lower than that of the control group(15%), and the difference was statistically significant(P<0.05). Conclusion Preoperative statin therapy has significant effect on coronary intervention in patients with coronary heart disease.It can promote the stability of the body and prevent adverse cardiovascular events. It is worthy of clinical application.
作者 曾庆宏 夏金兰 刘大勇 严新美 胡小武 Zeng Qinghong;Xia Jinlan;Liu Dayong;Yan Xinmei;Hu Xiaowu(Jiangxi Xinyu People' s Hospital, Xinyu, Jiangxi, 338000, China)
出处 《当代医学》 2019年第14期76-78,共3页 Contemporary Medicine
关键词 冠心病 冠脉介入术 阿托伐他汀 强化他汀 Coronary heart disease Percutaneous coronary intervention Atorvastatin Intensive statin
  • 相关文献

参考文献10

二级参考文献104

  • 1王剑锋.瑞舒伐他汀对冠心病患者血清CTRP9及ghrelin水平的影响[J].中国生化药物杂志,2014,34(1):113-115. 被引量:5
  • 2卢新政.2007年欧洲高血压协会和欧洲心脏病学会高血压指南新亮点[J].中华高血压杂志,2007,15(9):708-710. 被引量:19
  • 3李菁.不同剂量阿托伐他汀短期治疗对冠脉介入治疗患者术后心肌损伤的影响[D].北京:首都医科大学,2011.
  • 4Brener SJ, Ellis SG, Schneider J, et al.Frequency and long-termimpact of myonecrosis after coronary stenting[J].Eur Heart J,2002, 23(11):869-76.
  • 5Babu GG, Walker JM, Yellon DM, et al.Peri-procedural myocardialinjury during percutaneous coronary intervention:an importanttarget for cardioprotection[J].Eur Heart J, 2011, 32(1):23-31.
  • 6Testa L, Van Gaal WJ, Biondi Zoccai GG, et al.Myocardialinfarction after percutaneous coronary intervention:a meta-analysisof troponin elevation applying the new Universal definition[J].QJM, 2009, 102(6):369-78.
  • 7Radcliffe KA, Campbell WW.Statin myopathy[J].Curr NeurolNeurosci Rep, 2008, 8(1):66-72.
  • 8Baigent C, Keech A, Kearney PM, et al.Efficacy and safety ofcholesterol-lowering treatment:prospective meta-analysis of datafrom 90,056 participants in 14 randomised trials of statins[J].Lancet, 2005, 366(9493):1267-78.
  • 9Anon.[7]heart protection study collaborative group,MRC/BHFheart protection study of cholesterol lowering with simvastatin in20,536 high-risk individuals:a randomised placebo-controlled trial[J].Lancet, 2002, 360(9326):7-22.
  • 10Shepherd J, Blauw GJ, Murphy MB, et al.Pravastatin in elderlyindividuals at risk of vascular disease (PROSPER):a randomisedcontrolled trial [J].Lancet, 2002, 360(9346):1623-30.

共引文献139

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部